RealTime Dynamix™: Multiple Sclerosis US2018-09-21T16:39:39+00:00

All Reports

Reports / Neurology Reports / RealTime Dynamix: Multiple Sclerosis US

RealTime Dynamix: Multiple Sclerosis US (quarterly)

The US multiple sclerosis (MS) market is more dynamic and complex than ever with several clinically distinct disease-modifying therapies (DMTs) currently available, including Genentech’s Ocrevus for primary progressive MS (PPMS) as well as relapsing forms of MS (RMS), and an active late-stage DMT pipeline. In addition, building on the first generic DMT launch in 2015, the availability of multiple generic glatiramer acetate options, as well as the possibility of oral generics over the next few years, will result in a major future shift in the landscape in the face of increasing payer pressure.

RealTime Dynamix™: Multiple Sclerosis (US) provides a close-quarters analysis of key performance metrics, focusing on brand gains and losses, industry contact rates, familiarity and adoption rates of recently launched products, and awareness of products in development. Product perceptions, disease awareness and attitudes, practice management and other topics are rotated throughout the year to provide an ongoing probe of the crucial drivers of change. This ongoing, independent insights series allows marketing professionals to keep abreast of and quickly react to market changes by providing critical information that will support their commercial strategies in the MS space.

Each quarter, ~100 US neurologists provide their responses to an online survey. Respondents are recruited from the Spherix Network, a proprietary group of clinical neurologists meeting our strict screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output. Additionally, this gives us the opportunity to more easily revisit physicians in order to uncover even more insight on strategically important findings.

This quarterly report has been fielded since Q1 2016.

Learn more about RealTime Dynamix™ reports here.

  • How is the current and near-term landscape for the MS market evolving?
  • What are the critical opportunities and barriers to growth for each brand and class?
  • How is Ocrevus impacting the RMS and PPMS markets?
  • How is the availability of multiple generic glatiramer acetate agents impacting the market? To what extent is use driven by neurologist choice versus payer mandate?
  • How is the treatment algorithm changing with increasing oral DMT experience and expanding options within the monoclonal antibody DMT class?
  • To what degree do neurologists have strong preferences for specific brands within the DMT classes? How are the DMTs delivering on the key attributes and on typical patient types?
  • With fewer opportunities for personal interactions, what the best channels for industry to share product information with neurologists?
  • How often are patients requesting specific DMT brands?
  • What are neurologists’ perceptions of late-stage pipeline assets and how do they anticipate incorporating these products into their MS treatment?

Commercial Products
Bayer (Betaseron), Biogen [Avonex, Plegridy, Tecfidera, Tysabri, Zinbryta (with AbbVie)], EMD Serono (Rebif), Genentech (Ocrevus, Rituxan), Genzyme (Aubagio, Lemtrada), Mylan (generic glatiramer acetate), Novartis (Gilenya, Extavia), Sandoz (Glatopa), Teva (Copaxone)

Pipeline Agents
AB Science (masitinib), Biogen [opicinumab, ALKS 8700 (with Alkermes)], Celgene/Receptos (ozanimod), J&J/Actelion (ponesimod), MedDay (MD-1003), Merck Serono (Mavenclad), Novartis (siponimod, ofatumumab), TG Therapeutics (ublituximab)

Download Report Overview (PDF)

RELATED CONTENT

Genentech’s Ocrevus Positioning as an Appropriate First-Line Option in Relapsing Remitting Multiple Sclerosis Appears to Be Resonating With a Subset of U.S. Neurologists – September 19, 2018
>VIEW ARTICLE

>VIEW Q3 2018 SPOTLIGHT

A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech’s Ocrevus Prescribing Patterns – June 26, 2018
>VIEW ARTICLE

>VIEW Q2 2018 SPOTLIGHT

REQUEST MORE INFO